Drug Profile
Research programme: polymorphonuclear neutrophil inhibitors (asthma) - InDex Pharmaceuticals
Alternative Names: DIMS 0001Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InDex Pharmaceuticals
- Class Oligonucleotides
- Mechanism of Action Neutrophil inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Sweden (Parenteral)